首页> 外文OA文献 >RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study

【2h】

RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study

机译：RPC4046，一种新型抗白细胞介素-13抗体，嵌段IL-13与IL-13α1和α2受体结合：随机，双盲，安慰剂控制的剂量升级首先 - 人类研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Catherine S. Tripp; Carolyn Cuff; Andrew L. Campbell; Barbara A. Hendrickson; Jeff Voss; Terry Melim; Chengbin Wu; Andrew D. Cherniack; Kenneth Kim;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study [J] . Catherine S. Tripp, Carolyn Cuff, Andrew L. Campbell, Advances in therapy. . 2017,第6期

机译：RPC4046，一种新型抗白细胞介素-13抗体，阻断IL-13与IL-13α1和α2受体结合：随机，双盲，安慰剂控制，剂量升级首先 - 人类研究
2. THE CHARACTERIZATION OF RPC4046, A NOVEL ANTI-IL13 MONOCLONAL ANTIBODY THAT BLOCKS BINDING TO IL-13 RECEPTOR alpha 1 AND alpha 2 IN DEVELOPMENT FOR EOSINOPHILIC ESOPHAGITIS: RESULTS OF A FIRST-IN-HUMAN STUDY. [J] . Tripp C., Campbell A., Hendrickson B., Annals of allergy, asthma, and immunology . 2014,第5Suppla1期

机译：RPC4046的特征，这是一种新型的抗IL13单克隆抗体，在嗜酸性食管癌的发展中与IL-13受体alpha 1和alpha 2结合：这是一项首次人间研究的结果。
3. A Randomized, Double-Blind, Placebo-Controlled Trial of a Novel Recombinant, Humanized, Anti-Interleukin-13 Monoclonal Antibody (RPC4046) in Patients with Active Eosinophilic Esophagitis: Results of the HEROES Study [J] . Dellon Evan S., Collins Margaret, Assouline-Dayan Yehudith, The American Journal of Gastroenterology . 2016,第Suppla1期

机译：新型重组，人源化，抗白介素13单克隆抗体（RPC4046）在活动性嗜酸性食管炎患者中的随机，双盲，安慰剂对照试验：HEROES研究的结果
4. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
5. RPC4046 A Novel Anti-interleukin-13 Antibody Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized Double-Blind Placebo-Controlled Dose-Escalation First-in-Human Study [O] . Catherine S. Tripp, Carolyn Cuff, Andrew L. Campbell, -1

机译：RPC4046一种新型抗白介素13抗体阻断IL-13与IL-13α1和α2受体的结合：一项随机双盲安慰剂对照剂量递增的首次人类研究
6. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial [O] . Choy, E H S, Isenberg, D A, Garrood, T, 2002

机译：用抗白介素6受体单克隆抗体阻断白细胞介素6活性在类风湿关节炎中的治疗益处-一项随机，双盲，安慰剂对照的剂量递增试验

RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study

著录项

引文网络

相似文献

相关主题

期刊订阅